Evaluation of Published Clinical Scores for the Prediction of Cardiometabolic Risk in the SEMEOTICONS Project

Melania Gaggini, Renata De Maria, Chiara Saponaro, Emma Buzzigoli, Demetrio Ciociaro, Sylvie Normand, Giuseppe Coppini, Martine Laville, Paolo Marraccini, Amalia Gastaldelli

Abstract

Cardiovascular and metabolic diseases are the major causes of morbidity and mortality in the Western Countries. Metabolic syndrome (defined as 3 out of 5 factors among increased waist circumference, hypertension, high blood glucose, high triglyceride and low high density lipoprotein (HDL) cholesterol concentrations) is associated with increased cardiometabolic risk. Other indexes have been proposed and validated, based on the measurement of plasma concentration of lipids, glucose and liver enzymes. In the SEMEOTICONS project we plan to measure parameters related to increased cardiometabolic risk, e.g. skin accumulation of cholesterol and advanced glycated end products, liver enzyme alteration by changing in skin and eye color and obesity. The results will allow to evaluate cardiometabolic risk using non invasive clinical parameters. The new score obtained will be compared with previously validated indexes. In this paper we have evaluated the most common cardiometabolic risk scores i.e., VAI (Visceral Adiposity Index), HTG- Waist (Hypertriglyceridemic Waist), FLI (Fatty Liver Index) and LAP (Lipid Accumulation Product), that we will use during the project.

References

  1. Alberti, K. G., R. H. Eckel, et al., 2009. "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity." Circulation 120(16): 1640-1645.
  2. Alberti, K. G., P. Zimmet, et al., 2006. "Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation." Diabet Med 23(5): 469-480.
  3. Amato, M. C., C. Giordano, et al., 2010. "Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk." Diabetes Care 33(4): 920-922.
  4. Andreozzi, F., A. Gastaldelli, et al., 2013. "Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction." Atherosclerosis 229(2): 277-281.
  5. Anstee, Q. M., G. Targher, et al., 2013. "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis." Nat Rev Gastroenterol Hepatol 10(6): 330- 344.
  6. Arsenault, B. J., I. Lemieux, et al., 2010. "The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study." CMAJ 182(13): 1427- 1432.
  7. Balkau, B., C. Lange, et al., 2010. "Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study." BMC Gastroenterol 10: 56.
  8. Bedogni, G., S. Bellentani, et al., 2006. "The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population." BMC Gastroenterol 6: 33.
  9. Bedogni, G., H. S. Kahn, et al., 2010. "A simple index of lipid overaccumulation is a good marker of liver steatosis." BMC Gastroenterol 10: 98.
  10. Blackburn, P., I. Lemieux, et al., 2009. "The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile." Metabolism 58(8): 1123-1130.
  11. Calori, G., G. Lattuada, et al., 2011. "Fatty liver index and mortality: the Cremona study in the 15th year of follow-up." Hepatology 54(1): 145-152.
  12. Carey, V. J., E. E. Walters, et al., 1997. "Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study." Am J Epidemiol 145(7): 614-619.
  13. de Graaf, F. R., J. D. Schuijf, et al., 2010. "Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography." Am J Cardiol 106(12): 1747- 1753.
  14. Despres, J. P., S. Moorjani, et al., 1990. "Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease." Arteriosclerosis 10(4): 497- 511.
  15. Ferrannini, E., 2007. "Metabolic syndrome: a solution in search of a problem." J Clin Endocrinol Metab 92(2): 396-398.
  16. Gastaldelli, A., M. Kozakova, et al., 2009. "Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population." Hepatology 49(5): 1537-1544.
  17. Grundy, S. M., G. J. Balady, et al., 1998. "Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association." Circulation 97(18): 1876-1887.
  18. Hentges, P. P. and C. J. Huerter, 2001. "Eruptive xanthomas and chest pain in the absence of coronary artery disease." Cutis 67(4): 299-302.
  19. Ioachimescu, A. G., D. M. Brennan, et al., 2010. "The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study." Obesity (Silver Spring) 18(9): 1836-1844.
  20. Kahn, H. S., 2005. "The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison." BMC Cardiovasc Disord 5: 26.
  21. Kissebah, A. H., D. S. Freedman, et al., 1989. "Health risks of obesity." Med Clin North Am 73(1): 111-138.
  22. Kozakova, M., C. Palombo, et al., 2012. "Fatty liver index, gamma-glutamyltransferase, and early carotid plaques." Hepatology 55(5): 1406-1415.
  23. Lemieux, I., P. Poirier, et al., 2007. "Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?" Can J Cardiol 23 Suppl B: 23B-31B.
  24. Morelli, M., M. Gaggini, et al., 2013. "Ectopic fat: the true culprit linking obesity and cardiovascular disease?" Thromb Haemost 110(4): 651-660.
  25. NCEP-ATPIII, a., 2001. "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)." JAMA 285(19): 2486-2497.
  26. Pejic, R. N. and D. T. Lee, 2006. "Hypertriglyceridemia." J Am Board Fam Med 19(3): 310-316.
  27. Perk, J., G. De Backer, et al., 2012. "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)." Eur Heart J 33(13): 1635-1701.
  28. Petta, S., M. Amato et al., 2010. "Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1." Hepatology 52(5): 1543-1552.
  29. Petta, S., M. C. Amato, et al., 2012. "Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease." Aliment Pharmacol Ther 35(2): 238-247.
  30. Pouliot, M. C., J. P. Despres, et al., 1992. "Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels." Diabetes 41(7): 826-834.
  31. Rexrode, K. M., J. E. Buring, et al., 2001. "Abdominal and total adiposity and risk of coronary heart disease in men." Int J Obes Relat Metab Disord 25(7): 1047- 1056.
  32. Rexrode, K. M., V. J. Carey, et al., 1998. "Abdominal adiposity and coronary heart disease in women." JAMA 280(21): 1843-1848.
  33. Taverna, M. J., M. T. Martinez-Larrad, et al., 2011. "Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population." Eur J Endocrinol 164(4): 559-567.
  34. Turkoglu, C., B. S. Duman, et al., 2003. "Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature." Obes Surg 13(5): 699-705.
Download


Paper Citation


in Harvard Style

Gaggini M., De Maria R., Saponaro C., Buzzigoli E., Ciociaro D., Normand S., Coppini G., Laville M., Marraccini P. and Gastaldelli A. (2014). Evaluation of Published Clinical Scores for the Prediction of Cardiometabolic Risk in the SEMEOTICONS Project . In Proceedings of the International Conference on Health Informatics - Volume 1: SUPERHEAL, (BIOSTEC 2014) ISBN 978-989-758-010-9, pages 599-605. DOI: 10.5220/0004939005990605


in Bibtex Style

@conference{superheal14,
author={Melania Gaggini and Renata De Maria and Chiara Saponaro and Emma Buzzigoli and Demetrio Ciociaro and Sylvie Normand and Giuseppe Coppini and Martine Laville and Paolo Marraccini and Amalia Gastaldelli},
title={Evaluation of Published Clinical Scores for the Prediction of Cardiometabolic Risk in the SEMEOTICONS Project},
booktitle={Proceedings of the International Conference on Health Informatics - Volume 1: SUPERHEAL, (BIOSTEC 2014)},
year={2014},
pages={599-605},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0004939005990605},
isbn={978-989-758-010-9},
}


in EndNote Style

TY - CONF
JO - Proceedings of the International Conference on Health Informatics - Volume 1: SUPERHEAL, (BIOSTEC 2014)
TI - Evaluation of Published Clinical Scores for the Prediction of Cardiometabolic Risk in the SEMEOTICONS Project
SN - 978-989-758-010-9
AU - Gaggini M.
AU - De Maria R.
AU - Saponaro C.
AU - Buzzigoli E.
AU - Ciociaro D.
AU - Normand S.
AU - Coppini G.
AU - Laville M.
AU - Marraccini P.
AU - Gastaldelli A.
PY - 2014
SP - 599
EP - 605
DO - 10.5220/0004939005990605